|
Orthologous residues
|
|
Btk (human): Y551‑p, Btk (mouse): Y551‑p, Btk (rat): Y552‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
immunoprecipitation, mutation of modification site, phospho-antibody, western blotting
|
|
Disease tissue studied:
lymphoma, B cell lymphoma
|
|
Relevant cell lines - cell types - tissues:
293T (epithelial), DT40 (B lymphocyte) [BLNK (human)]
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Comments:
Syc phosphorylates Btk and enhances Btk activity in the presence of BLNK.
|
|
Upstream Regulation
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
|
|
Syk (human), BLNK (human)
|
|
increase
|
Blnk is required for Syk phosphorylation and activation of Btk.
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
enzymatic activity, induced, molecular association, regulation
|
|
Modification regulates interactions with:
|
|
Interacting molecule
|
Interacting domains
|
Effect
|
Consequences (function)
|
Consequences (process)
|
Detection assays
|
|
BLNK (human)
|
|
Induces
|
|
|
co-immunoprecipitation
|
|
|
Comments:
Btk-SH2 domain is reqired for Syk-dependent phosphorylation.
|
